Key result
Supervised high-intensity interval training mitigated the chemotherapy-induced decline in relative exercise capacity compared to control in young women with breast cancer.
Why the study?
Chemotherapy in younger breast cancer patients induces fatigue and adverse effects, and it was unknown whether supervised HIIT during chemotherapy impacts cardiorespiratory fitness in this group.
Does supervised high-intensity interval training mitigate the decline in cardiorespiratory fitness in young breast cancer patients undergoing chemotherapy?
RCT (n=26)
Open-label
Stratified randomization
No
Does supervised high-intensity interval training mitigate the decline in cardiorespiratory fitness in young breast cancer patients undergoing chemotherapy?
Supervised high-intensity interval training during chemotherapy significantly mitigates the decline in cardiorespiratory fitness and exercise capacity in young women with breast cancer.
Answers are grounded in this paper and cite their sources.
HIIT may reduce chemotherapy-induced fatigue in younger BC patients; leaves open efficacy on outcomes pending RCTs.
PURPOSE: Younger women are diagnosed more often with aggressive breast cancer (BC) subtypes, the treatment of which usually incorporates chemotherapy. Physical training plays a significant role in mitigating the adverse effects of systemic cancer therapy, improving quality of life, and potentially enhancing treatment efficacy. High-intensity interval training (HIIT) emerged as a promising intervention to counteract the fatigue induced by chemotherapy, which in younger women often causes depression and disruption of employment. This study aimed to investigate whether supervised HIIT employed concurrently with chemotherapy impacts the cardiorespiratory fitness of young BC patients. METHODS: Twenty-six young (18-40 years old) BC patients scheduled for chemotherapy were randomised to intervention comprising supervised HIIT employed concurrently with chemotherapy or no supervised training (control) for 6 months. Outcomes measured using cardiopulmonary exercise testing (CPET) and non-invasive cardiac output testing were cardiorespiratory fitness and cardiac output. RESULTS: from 33.630 to 29.540 ml/kg/min for HIIT group and from 29.679 to 22.571 ml/kg/min for control group (ANCOVA p = 0.018, ES = 0.469), and also a mitigated the decrease in exercise time from 685.600 to 666.500 s for HIIT group and from 703.357 to 555.500 s for control group (ANCOVA p = 0.008, ES = 0.815) measured during CPET. CONCLUSIONS: Supervised HIIT implemented alongside chemotherapy can mitigate the decline in cardiorespiratory fitness caused by BC chemotherapy in young patients. TRIAL REGISTRATION: The study was registered in the clinicaltrials.gov registry (#NCT06190600) on 2024-01-05, retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Dudek et al. (2025) conducted an RCT in Breast cancer (n=26). Supervised high-intensity interval training (HIIT) vs. No supervised training (control) was evaluated on Relative peak VO2 (ml/kg/min) (ES 0.469, p=0.018). Supervised high-intensity interval training mitigated the chemotherapy-induced decline in relative exercise capacity compared to control in young women with breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: